Trial Profile
SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Estradiol/norethisterone acetate/relugolix (Primary) ; Relugolix (Primary)
- Indications Dysmenorrhoea; Pelvic pain
- Focus Therapeutic Use
- Acronyms SPIRIT EXTENSION; SPIRIT LTE study
- Sponsors Myovant Sciences
- 01 Mar 2024 Results (n=681 at 52 weeks and n=501 at 104 weeks) assessing safety and efficacy of Relugolix CT, published in the Human Reproduction.
- 15 Sep 2023 According to Sumitomo Pharma media release, the Committee for Medicinal Products for Human Use ("CHMP") of EMA has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO. The European Commission will review the CHMP recommendation and a final decision on the Marketing Authorization Application is expected to be available in the coming months. This application is supported by SPIRIT 1 and SPIRIT 2 and 80-week, open-label extension studies.
- 27 Jun 2023 Status changed from active, no longer recruiting to completed.